10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

x Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2009

¨ Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from              to

Commission File Number: 0-28666

AMERICAN BIO MEDICA CORPORATION

 (Exact name of registrant as specified in its charter)

New York	14-1702188
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

122 Smith Road, Kinderhook, New York	12106
(Address of principal executive offices)	(Zip Code)

518-758-8158

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days     x     Yes     o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files)        x Yes     o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer       o	Accelerated filer                           o
Non-accelerated filer         o	Smaller reporting company          x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)

o  Yes     x  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

21,744,768 Common Shares as of May 14, 2009

American Bio Medica Corporation

Index to Quarterly Report on Form 10-Q

For the quarter ended March 31, 2009

		PAGE
PART I – FINANCIAL INFORMATION
Item 1.	Financial Statements
	Balance Sheets as of March 31, 2009 (unaudited) and December 31, 2008	3
	Unaudited Statements of Operations for the three months ended March 31, 2009 and March 31, 2008	4
	Unaudited Statements of Cash Flows for the three months ended March 31, 2009 and March 31, 2008	5
	Notes to Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14
Item 4.	Controls and Procedures	14
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	14
Item 1A.	Risk Factors	14
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14
Item 3.	Defaults Upon Senior Securities	14
Item 4	Submission of Matters to a Vote of Security Holders	14
Item 5.	Other Information	14
Item 6.	Exhibits	15
Signatures

2

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

American Bio Medica Corporation

Balance Sheets

	March 31,			December 31,
	2009			2008
	(Unaudited)
ASSETS
Current assets
Cash and cash equivalents	$	592,000		$	201,000
Accounts receivable - net of allowance for doubtful accounts of $105,000 at both March 31, 2009 and December 31, 2008		1,391,000			1,161,000
Inventory – net of reserve for slow moving and obsolete inventory of $308,000 at both March 31, 2009 and December 31, 2008		5,021,000			5,552,000
Prepaid expenses and other current assets		107,000			97,000
Total current assets		7,111,000			7,011,000
Property, plant and equipment, net		1,897,000			1,961,000
Debt issuance costs		109,000			117,000
Other assets		44,000			47,000
Total assets	$	9,161,000		$	9,136,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable	$	1,540,000		$	1,568,000
Accrued expenses and other current liabilities		661,000			544,000
Wages payable		263,000			230,000
Line of credit		621,000			431,000
Current portion of long-term debt		1,067,000			1,098,000
Current portion of unearned grant		10,000			10,000
Total current liabilities		4,162,000			3,881,000
Other long-term liabilities		204,000			207,000
Long-term debt		759,000			760,000
Unearned grant		30,000			30,000
Total liabilities		5,155,000			4,878,000
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at March 31, 2009 and December 31, 2008
Common stock; par value $.01 per share; 50,000,000 shares authorized; 21,744,768 issued and outstanding at both March 31, 2009 and December 31, 2008		217,000			217,000
Additional paid-in capital		19,279,000			19,279,000
Accumulated deficit		(15,490,000	)		(15,238,000	)
Total stockholders’ equity		4,006,000			4,258,000
Total liabilities and stockholders’ equity	$	9,161,000		$	9,136,000

The accompanying notes are an integral part of the financial statements

3

American Bio Medica Corporation

Statements of Operations

(Unaudited)

	For The Three Months Ended
	March 31
	2009			2008
Net sales	$	2,255,000		$	3,299,000
Cost of goods sold		1,336,000			1,872,000
Gross profit		919,000			1,427,000
Operating expenses:
Research and development		101,000			138,000
Selling and marketing		498,000			768,000
General and administrative		524,000			683,000
		1,123,000			1,589,000
Operating loss		(204,000	)		(162,000	)
Other income (expense):
Interest income		1,000			1,000
Interest expense		(47,000	)		(34,000	)
Other expense		(2,000	)		(4,000	)
		(48,000	)		(37,000	)
Loss before tax		(252,000	)		(199,000	)
Income tax
Net loss after tax	$	(252,000	)	$	(199,000	)
Basic and diluted loss per common share	$	(0.01	)	$	(0.01	)
Weighted average number of shares outstanding – basic & diluted		21,744,768			21,744,768

The accompanying notes are an integral part of the financial statements

4

American Bio Medica Corporation

 Statements of Cash Flows

(Unaudited)

	For The Three Months Ended
	March 31,
	2009			2008
Cash flows from operating activities:
Net loss	$	(252,000	)	$	(199,000	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation		86,000			92,000
Loss on disposal of fixed assets		2,000			4,000
Amortization of debt issuance costs		8,000
Changes in:
Accounts receivable		(230,000	)		(143,000	)
Inventory		531,000			(79,000	)
Prepaid expenses and other current assets		(10,000	)		(46,000	)
Other non-current assets		3,000			50,000
Accounts payable		(28,000	)		236,000
Accrued expenses and other current liabilities		117,000			205,000
Patent sublicense					(50,000	)
Wages payable		33,000			8,000
Other long-term liabilities		(3,000	)
Net cash provided by operating activities		257,000			78,000
Cash flows from investing activities:
Purchase of property, plant and equipment		(24,000	)		(7,000	)
Net cash used in investing activities		(24,000	)		(7,000	)
Cash flows from financing activities:
Payments on debt financing		(32,000	)		(30,000	)
Net proceeds from line of credit		190,000
Net cash provided by / (used in) financing activities		158,000			(30,000	)
Net increase in cash and cash equivalents		391,000			41,000
Cash and cash equivalents - beginning of period		201,000			336,000
Cash and cash equivalents - end of period	$	592,000		$	377,000
Supplemental disclosures of cash flow information
Cash paid during period for interest	$	65,000		$	34,000

The accompanying notes are an integral part of the financial statements

5

Notes to financial statements (unaudited)

March 31, 2009

Note A - Basis of Reporting

The accompanying unaudited interim financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all information and footnotes required by generally accepted accounting principles for complete financial statement presentation. In the opinion of management, the interim financial statements include all normal, recurring adjustments, which are considered necessary for a fair presentation of the financial position of the Company at March 31, 2009, and the results of its operations and cash flows for the three month periods ended March 31, 2009 and March 31, 2008.

Operating results for the three months ended March 31, 2009 are not necessarily indicative of results that may be expected for the year ending December 31, 2009. Amounts at December 31, 2008 are derived from the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008.

 During the three months ended March 31, 2009, there were no significant changes to the Company's critical accounting policies, which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

The preparation of these interim financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, including those related to product returns, bad debts, inventories, income taxes, warranty obligations, and contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

These unaudited interim financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The Company's independent registered public accounting firm's report of the financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, contained an explanatory paragraph regarding the Company's ability to continue as a going concern.

Recently Adopted Accounting Standards

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (“SFAS No. 157”). SFAS No. 157 established a common definition for fair value to be applied to U.S. GAAP guidance requiring use of fair value, established a framework for measuring fair value, and expanded disclosure about such fair value measurements. SFAS No. 157 became effective for our financial assets and liabilities on January 1, 2008.  Certain provisions of SFAS No. 157 relating to the Company’s nonfinancial assets and liabilities became effective January 1, 2009. The implementation of SFAS No. 157 does not materially affect the Company’s interim financial statements.

SFAS No. 157 establishes a hierarchy for ranking the quality and reliability of the information used to determine fair values.  SFAS No. 157 requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1:  Unadjusted quoted market prices in active markets for identical assets or liabilities.

Level 2:  Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices are observable for the asset or liability.

6

Level 3:  Unobservable inputs for the asset or liability.

The Company endeavors to utilize the best available information in measuring fair value.  Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement.  The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments:

Cash Equivalents – The carrying amount reported in the balance sheet for cash equivalents approximates its fair value due to the short-term maturity of these instruments.

Line of Credit and Long-Term Debt – The carrying amounts of the Company’s borrowings under its line of credit agreement and other long-term debt approximates fair value, based upon current interest rates.

In December 2007, the FASB issued SFAS No. 141(R), “Business Combinations,” (“SFAS No. 141(R)”) and SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements” (“SFAS No. 160”). Effective for the Company as of January 1, 2009, SFAS No. 141(R) requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors and other users all of the information they need to evaluate and understand the nature and financial effect of the business combination. Effective January 1, 2009, SFAS No. 160 requires all entities to report noncontrolling (minority) interests in subsidiaries as equity in the consolidated financial statements. Moreover, SFAS No. 160 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. The Company adopted SFAS No. 141(R) and SFAS No. 160 as of January 1, 2009 and this adoption had no impact on our interim financial statements.

In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities – an Amendment of FASB Statement No. 133” (“SFAS No. 161”). SFAS No. 161 expands the disclosure requirements in SFAS No. 133, regarding an entity’s derivative instruments and hedging activities. SFAS No. 161 is effective on January 1, 2009.  The Company adopted SFAS No. 161 as of January 1, 2009 and this adoption had no impact on our interim financial statements.

Note B – Net Loss Per Common Share

Basic net loss per common share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted net loss per common share includes the weighted average dilutive effect of stock options and warrants.

Potential common shares outstanding as of March 31, 2009 and 2008:

	March 31, 2009		March 31, 2008
Warrants		75,000		150,000
Options		3,762,080		3,768,080

For the three months ended March 31, 2009 and March 31, 2008, the number of securities not included in the diluted EPS because the effect would have been anti-dilutive were 3,837,080 and 3,918,080, respectively.

Note C – Litigation

The Company has been named in legal proceedings in connection with matters that arose during the normal course of its business, and that in the Company’s opinion are not material.  While the ultimate result of any litigation cannot be determined, it is management’s opinion, based upon consultation with counsel, that it has adequately provided for losses that may be incurred related to these claims.  If the Company is unsuccessful in defending any or all of these claims, resulting financial losses could have an adverse effect on the financial position, results of operations and cash flows of the Company.

7

Note D – Reclassifications

Certain items have been reclassified to conform to the current presentation.

Note E – Line of Credit and Long-Term Debt

Real Estate Mortgage

On November 6, 2006, the Company obtained a real estate mortgage (“Real Estate Mortgage”) related to its facility in Kinderhook, New York. The loan through First Niagara Financial Group (“FNFG”) is in the amount of $775,000 and has a term of ten (10) years with a twenty (20) year amortization. The interest rate is fixed at 7.50% for the first five (5) years. Beginning with year six (6) and through the end of the loan term, the rate changes to 2% above the Federal Home Loan Bank of New York five (5) year term, fifteen (15) year Amortization Advances Rate. The Company’s monthly payment is $6,293 with the final payment being due on December 1, 2016. The loan is collateralized by the Company's facility in Kinderhook, New York and its personal property.  The amount outstanding on this mortgage was $734,000 and $739,000 at March 31, 2009 and December 31, 2008, respectively.

Line of Credit

The Company has a Line of Credit with FNFG. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on August 8, 2008, effective August 1, 2008, the Company and FNFG entered into an amendment to the original Loan Documents (the “Amendment”). The Amendment combined two lines of credit already in place with FNFG into one line of credit (the “Line of Credit”) and amended certain terms related to the Line of Credit. Pursuant to the Amendment, the maximum amount available under the Line of Credit was lowered to $750,000, and the maturity date of the Line of Credit was April 1, 2009. The interest rate on the Line of Credit was prime plus 1%.  Pursuant to the Amendment, the Company was required to maintain certain financial covenants; the Company’s monthly net loss was not to exceed $75,000 during any month and, while any loans or commitments are outstanding and due FNFG, the Company was to maintain a minimum debt service coverage ratio of 1.10x, to be measured at December 31, 2008. The minimum debt service coverage ratio is defined as net income plus interest expense plus depreciation plus expense related to the amortization of derivative securities divided by required principal payments over the preceding twelve months plus interest expense. There is no requirement for annual repayment of all principal on this Line of Credit and it is payable on demand. The amount outstanding on the Line of Credit was $621,000 at March 31, 2009 and $431,000 at December 31, 2008.

Term Note

On January 22, 2007, the Company entered into a Term Note with FNFG in the amount of $539,000 (the “Note”). The term of the Note is 5 years with a fixed interest rate of 7.17%. The Company’s monthly payment is $10,714 with the final payment being due on January 23, 2012. The Company has the option of prepaying the Note in full or in part at any time during the term without penalty. The loan is secured by Company assets now owned or hereafter acquired. The proceeds received were used for the purchase of automation equipment to enhance the Company's manufacturing process in its New Jersey facility. The amount outstanding on this Note was $330,000 and $356,000 at March 31, 2009 and December 31, 2008, respectively.

Forbearance Agreement

On February 4, 2009, although the Company was current with the payment schedules for its Real Estate Mortgage, Term Note and Line of Credit, the Company received a letter from FNFG notifying the Company that an event of default had occurred under the Loan Documents related to the Line of Credit, Real Estate Mortgage and Term Note (the “Credit Facilities”); the event of default occurred as a result of, among other things, the Company’s failure to comply with the maximum monthly net loss covenant set forth in the Amendment.  Pursuant to the terms of the Loan Documents, all obligations of the Company to FNFG under the Loan Documents could be declared by FNFG to be immediately due and payable. The principal amount totaled $1,636,635.97, plus interest and other charges through February 4, 2009 (collectively, the “Debt”).

The February 4, 2009 notice also stated that, as an accommodation to the Company, FNFG decided not to immediately accelerate the Debt, and that they expected the Company to enter into a Forbearance Agreement with FNFG memorializing measures and conditions required by FNFG. FNFG also notified the Company that they were reducing the commitment on the Line of Credit from $750,000 to $650,000 and placing a hold on one of our accounts held at FNFG.

8

On March 12, 2009, the Company entered into a Forbearance Agreement (the “Agreement”) with FNFG. The Agreement addresses the Company’s non-compliance with the maximum monthly net loss and the minimum debt service coverage ratio covenants (“Existing Defaults”) under the Loan Documents related to the Debt. Under the terms of the Agreement, FNFG will forbear from exercising its rights and remedies arising under the Loan Documents from the Existing Defaults. The Agreement is in effect until (i) June 1, 2009; or (ii) the date on which FNFG elects to terminate the Agreement upon the occurrence of an event of default under the Agreement or under the Loan Documents (other than an Existing Default); or (iii) the date on which any subsequent amendment to the Agreement becomes effective (the “Forbearance Period”).

During the Forbearance Period, FNFG will continue to place a hold on one of the Company’s accounts but agreed to release up to $5,000 per month from the account to be used for the purpose of paying a financial advisory firm engaged by the Company to find and evaluate alternative funding sources; the financial advisory firm was referred to the Company by FNFG. The Company began making payments to this financial advisory firm on March 1, 2009. As of the date of this report there is a balance of $86,000 in this account.

The maximum available under the Line of Credit during the Forbearance Period will be the lesser of $650,000, or the Net Borrowing Capacity. Net Borrowing Capacity is defined as Gross Borrowing Capacity less the Inventory Value Cap. Gross Borrowing Capacity is defined as the sum of (i) 80% of eligible accounts receivable, (ii) 20% of raw material inventory and (iii) 40% of finished goods inventory. Inventory Value Cap is defined as the lesser of $400,000, or the combined value of items (ii) and (iii) of Gross Borrowing Capacity. Since September 2008, the Company’s Net Borrowing Capacity has declined from $1,195,000 to $910,000 as of the date of this report.

During the Forbearance Period, interest will accrue on the Line of Credit at the rate of prime plus 4%, an increase from prime plus 1%. Interest accruing on the Real Estate Mortgage during the Forbearance Period remains unchanged at the fixed rate of 7.5% and interest on the Note remains unchanged at the fixed rate of 7.17%. In the event of default under the Agreement, interest under the Line of Credit will increase to the greater of prime plus 6% or 10%. The Line of Credit terminates on June 1, 2009.

Under the Agreement, during the Forbearance Period: FNFG waives any further default relating to the maximum monthly net loss covenant and minimum debt service coverage ratio provided the Company shows a net loss no greater than $300,000 for the quarter ending March 31, 2009, and on or before May 1, 2009, the Company is required to provide to FNFG a legally binding and executed commitment letter from a bona-fide third party lender setting forth the terms of a full refinancing of the Debt to close on or before June 1, 2009.

The Company is in compliance with the net loss requirement for the quarter ended March 31, 2009 and remains in compliance with its payment schedules related to the Credit Facilities. On April 1, 2009, the Company entered into a non-binding proposal with a third party related to a revolving secured line of credit of up to $1,500,000. The financing is subject to completion of the third party’s due diligence. In connection with this proposal, the Company has paid the third party a non-refundable deposit of $12,500, for their time and costs involved in their due diligence review and evaluation.  FNFG authorized the release of these funds from the Company’s account currently frozen by FNFG.

On May 6, 2009, the Company entered into Letter Agreement related to the Forbearance Agreement of March 12, 2009. The Letter Agreement requires the Company to produce to FNFG, on or before May 15, 2009, a legally binding and executed commitment letter from a bona-fide third party lender setting forth the terms of a full refinancing of the Line of Credit to close on or before June 1, 2009. Furthermore, on or before June 1, 2009, the Company must produce to FNFG a legally binding and executed commitment letters from a bona-fide third party lender setting forth the terms of a full refinancing of the Term Note and the Real Estate Mortgage to close on or before July 1, 2009. As of the date of this report, the Company continues to work with the third party lender referenced above towards finalizing a loan commitment by May 15, 2009.

Copier Lease

On May 8, 2007, the Company purchased a copier through an equipment lease with RICOH in the amount of $17,000.  The term of the lease is five (5) years with an interest rate of 14.11%.  The amount outstanding on this lease was $12,000 and $13,000 at March 31, 2009 and December 31, 2008, respectively.

9

Series A Debenture Financing

On August 15, 2008, the Company completed its offering of the Series A Debentures and received gross proceeds of $750,000 (see Current Report on Form 8-K and amendment on Form 8-K/A-1 filed with the Commission on August 8, 2008 and August 18, 2008 respectively). The net proceeds of the offering of Series A Debentures were $631,000 after $54,000 of placement agent fees and expenses, legal and accounting fees of $63,000 and $2,000 of state filing fees. The securities issued in this transaction were sold pursuant to the exemption from registration afforded by Rule 506 under Regulation D ("Regulation D") as promulgated by the Commission under the Securities Act of 1933, as amended (the "1933 Act"), and/or Section 4(2) of the 1933 Act.

The Series A Debentures accrue interest at a rate of 10% per annum (payable by the Company semi-annually) and mature on August 1, 2012. The payment of principal and interest on the Series A Debentures is subordinate and junior in right of payment to all Senior Obligations, as defined under the Series A Debentures. Holders of the Series A Debentures will have a right of conversion of the principal amount of the Series A Debentures into shares (the “Conversion Shares”) of the common stock of the Company (“Common Stock”), at a conversion rate of 666.67 shares per $500 in principal amount of the Series A Debentures (representing a conversion price of approximately $0.75 per share). This conversion right can be exercised at any time, commencing the earlier of (a) one hundred twenty (120) days after the date of the Series A Debentures, or (b) the effective date of a Registration Statement to be filed by the Company with respect to the Conversion Shares. The Company has the right to redeem any Series A Debentures that have not been surrendered for conversion at a price equal to the Series A Debentures’ face value plus $0.05 per underlying common share, or $525 per $500 in principal amount of the Series A Debentures, representing an aggregate conversion price of $787,500. This redemption right can be exercised by the Company at any time within ninety (90) days after any date when the closing price of the Common Stock has equaled or exceeded $2.00 per share for a period of twenty (20) consecutive trading days.

As placement agent Cantone Research, Inc. (“CRI”) received a Placement Agent fee of $52,500, or 7% of the gross principal amount of Series A Debentures sold. In addition, the Company issued CRI a four (4) year warrant to purchase 30,450 shares of the Company’s common stock at an exercise price of $0.37 per share (the closing price of the Company’s common shares on the Closing Date) and a four (4) year warrant to purchase 44,550 shares of the Company’s common stock at an exercise price of $0.40 per share (the closing price of the Company’s common stock on the Series A Completion Date), (together the “Placement Agent Warrants”). All warrants issued to CRI were immediately exercisable upon issuance.

Pursuant to a Registration Rights Agreement, the Company was to use reasonable efforts to register the Conversion Shares and the shares of Common Stock issuable upon exercise of the Placement Agent Warrants, and the Company filed a Registration Statement on Form S-3 on April 15, 2009, and further amended the Registration Statement on May 5, 2009.

The Company has incurred $131,000 in costs related to the offering. Included in these costs was $12,000 of non-cash compensation expense related to the issuance of the Placement Agent Warrants to CRI. These costs will be amortized over the term of the Series A Debentures.  For the three months ended March 31, 2009, the Company amortized $8,000 of expense related to these debt issuance costs. The Company has also accrued $12,000 in interest expense at March 31, 2009 related to the Series A Debentures.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General

The following discussion of the Company's financial condition and the results of operations should be read in conjunction with the interim Financial Statements and Notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. This discussion contains, in addition to historical statements, forward-looking statements that involve risks and uncertainties. Our actual future results could differ significantly from the results discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the factors discussed in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008. Any forward-looking statement speaks only as of the date on which such statement is made and we do not intend to update any such forward-looking statements.

10

Overview

During the three months ended March 31, 2009, the Company sustained a net loss of $252,000 from net sales of $2,255,000. The Company had net cash provided by operating activities of $257,000 for the first three months of 2009.

During the first three months of 2009, the Company continued to take steps to improve its financial position. Beginning in April 2008, the Company implemented a number of cost cutting initiatives including but not limited to, reducing the number of employees in selling and marketing, research and development and general and administrative departments. The Company also continued to take steps to reduce manufacturing costs related to its products to increase the Company’s gross margin. Simultaneously with these efforts, the Company continues to focus on the development of new products to address market trends and needs.

The Company's continued existence is dependent upon several factors, including its ability to raise revenue levels and reduce costs to generate positive cash flows, and to sell additional shares of the Company's common stock to fund operations and/or obtain additional credit facilities, if and when necessary.

In March 2009, the Company was notified by the United States Patent & Trademark office that it will be granted two patents; one for its oral fluid drug testing product line and the other for its all inclusive urine point of collection drug test cup product line. With these grants, ABMC's intellectual property portfolio for its drug of abuse testing line will increase to 12 United States patents and 14 foreign patents, in addition to a number of pending patent applications both within the US and internationally.

Plan of Operations

The Company’s sales strategy continues to be a focus on direct sales, while identifying new contract manufacturing opportunities and pursuing new national accounts. During the three months ended March 31, 2009, the Company continued its program to market and distribute its urine and oral fluid based point of collection tests for drugs of abuse and its Rapid Reader® drug screen results and data management system. Contract manufacturing operations also continued in the three months ended March 31, 2009.

Results of operations for the three months ended March 31, 2009 compared to the three months ended March 31, 2008

NET SALES: Net sales for the quarter ended March 31, 2009 decreased $1,044,000 or 31.6% when compared to net sales for the quarter ended March 31, 2008. Sales in all markets continued to be affected by the global economic crisis and price pressures in the first quarter of 2009. Sales in our Corporate/Workplace market (which includes our national account division) continue to be negatively impacted as new and existing employment levels of our customers either remain lower or in some cases experienced further declines. Price pressure from foreign competitors in our Government/Corrections/Law Enforcement market also continues to negatively impact that market. Sales in our International markets also declined slightly in the first quarter of 2009. We expect to continue to see declines in the Corporate/Workplace market as a result of declines in the employment levels of our customers, and increased price pressure in the Government/Corrections/Law Enforcement market, until the economy begins to recover. We are optimistic that sales in our International markets will either recover or decline at a lower rate.  To combat the sales decline we are experiencing with our current customers in the Corporate/Workplace market, we hope to close new accounts (including but not limited to new national accounts). To combat the decline in the Government/Corrections/Law Enforcement market, we have started offering our customers a modified version of our Rapid TOX Cup® product, the Rapid TOX Cup II. Certain raw material costs associated with the Rapid TOX Cup II are lower, which means we can offer the Rapid TOX Cup II at a reduced cost to our customers, which we hope will allow us to be successful in combating the price pressures in the Government/Corrections/Law Enforcement market. We will continue to focus our sales efforts on national accounts, direct sales and contract manufacturing, while striving to reduce manufacturing costs, which could enable us to be more cost competitive.

11

When comparing the first quarter of 2009 to the first quarter of 2008, sales of Rapid TOX®, Rapid TOX Cup and Rapid STAT™ increased. Increases in these product lines were offset by declines in sales of InCup®, Rapid Drug Screen®, OralStat® and Rapid Reader®. While most of these declines are simply the result of our lower sales levels, some of the attrition in these product lines is a result of customers switching from one product line to another due to either increased ease of use (in the case of the OralStat and Rapid STAT) or lower cost (in the case of InCup and Rapid TOX Cup).

The Company’s contract manufacturing operations currently include the manufacture of a HIV test, a test for fetal amniotic membrane rupture, and a test for RSV. Contract manufacturing sales during the first quarter of 2009 totaled $94,000, down from $131,000 in the same period a year ago.

COST OF GOODS SOLD: Cost of goods sold for the three months ending March 31, 2009 increased to 59.2% of net sales, compared to 56.7% of net sales for the three months ending March 31, 2008. Beginning in the fourth quarter of fiscal year ended December 31, 2008, the unanticipated sharp decline in sales due to the downturn of the economy negatively impacted our gross profit margin; more specifically, our labor and overhead costs and raw material expenditures were not in line with the level of sales achieved. In the first quarter of 2009, we began reducing manufacturing labor and overhead costs and raw material expenditures in efforts to improve our gross profit margin going forward, anticipating that sales will either continue to stay at lower levels or further decline until the economy recovers. As a result of these efforts, we did see some positive impact on our gross profit margin in the first quarter of 2009, however, due to the timing of the efforts, the impact was not fully realized.

OPERATING EXPENSES: Operating expenses declined 29.3%, when comparing the first quarter of 2009 to the first quarter of 2008. As a percentage of sales, operating expenses were 49.8% of net sales in the first quarter of 2009, compared to 48.2% of net sales in the first quarter of 2008. To improve its results of operations during the global economic crisis, the Company implemented a number of cost cutting initiatives and these initiatives have resulted in decreases in expenses in all three divisions as described in the following detail:

           Research and development (“R&D”) expense

R&D expenses for the first three months of 2009 decreased 26.8% when compared to the first quarter of 2008. The greatest savings was in salary expense.  In June 2008, the Vice President of Product Development retired and the Company has not filled this position, nor do we expect to fill this position in the future. The R&D department continues to focus their efforts on the enhancement of current products and exploration of contract manufacturing opportunities.

Selling and marketing expense

Selling and marketing expenses for the first three months of 2009 decreased 35.2% when compared to the first quarter of 2008.  Reductions in sales salaries and commissions, sales employee related benefits, travel expense, trade show related expense, postage, royalty expense, consulting fees, and advertising expense were partially offset by increases in marketing salaries and marketing employee related benefits. A number of these reductions stem from our cost cutting initiatives that began in 2008.

In the first quarter of 2009, we continued to promote our products through selected advertising, participation at high profile trade shows and other marketing activities. Our direct sales force continued to focus their selling efforts in our targets markets, which include but are not limited to, Corporate/Workplace, and Government/Corrections/Law Enforcement. In addition, beginning in the fourth quarter of 2008, our direct sales force began to focus more efforts on the Clinical/Physician/Hospital market, as a result of our receipt of a CLIA (Clinical Laboratory Improvement Amendments) waiver related to our Rapid TOX product line. The Clinical Laboratory Improvement Amendments (CLIA) of 1988 established quality standards for laboratory testing to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test was performed. As a result, those using CLIA waived tests are not subject to the more stringent and expensive requirements of moderate or high complexity laboratories.

General and administrative (“G&A”) expense

G&A expenses for the first three months of 2009 decreased 23.3% when compared to the first quarter of 2008. Reductions in investor relations expense, quality assurance salaries and supplies, CLIA waiver expense, legal fees, patents, licenses and permits, training, computer supplies, General Service Administration fees, bad debts and bank service fees were partially offset by increases in G&A salaries, consulting fees, auto allowance, postage, repairs and maintenance, payroll service fees and depreciation.

12

Liquidity and Capital Resources as of March 31, 2009

The Company's cash requirements depend on numerous factors, including product development activities, sales and marketing efforts, market acceptance of its new products, and effective management of inventory levels in response to sales forecasts. The Company expects to devote substantial capital resources to continue product development, refine manufacturing efficiencies, and support direct sales efforts.  The Company will examine other growth opportunities including strategic alliances and expects such activities will be funded from existing cash and cash equivalents, issuance of additional equity or debt securities or additional borrowings subject to market and other conditions. The Company’s financial statements for the fiscal year ended December 31, 2008 were prepared assuming it will continue as a going concern. As of the date of this report, the Company does not believe that its current cash balances, together with cash generated from future operations and amounts available under our credit facilities will be sufficient to fund operations for the next twelve months. If cash generated from operations is not sufficient to satisfy our working capital and capital expenditure requirements, we will be required to sell additional equity or obtain additional credit facilities. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all.

The Company has a Line of Credit, a Real Estate Mortgage and a Term Note with FNFG (See Item I, Note E).

Working capital

The Company’s working capital decreased $181,000 at March 31, 2009, when compared to working capital at December 31, 2008. In the fourth quarter of 2008, the Company reclassified its long-term bank debt with FNFG to short-term as a result of the Company’s default under the Loan Documents related to our credit facilities with FNFG and the subsequent forbearance (See Item I, Note E).

The Company has historically satisfied its net working capital requirements through cash from operations, bank debt, occasional proceeds from the exercise of stock options and warrants (approximately $623,000 since 2002) and through the private placement of equity securities ($3,299,000 in gross proceeds since August 2001, with net proceeds of $2,963,000 after placement, legal, transfer agent, accounting and filing fees).

Dividends

The Company has never paid any dividends on its common shares and anticipates that all future earnings, if any, will be retained for use in the Company's business and it does not anticipate paying any cash dividends.

Cash Flows

Decreases in inventory and increases in accrued expenses and wages payable offset by increases in accounts receivable and decreases in accounts payable, resulted in cash provided by operations of $257,000 in the first three months of 2009.  The primary use of cash in the first quarter of 2009 was funding of operations.

Net cash used in investing activities in both the first quarter of both 2009 and 2008 was for investment in property, plant and equipment.

Net cash provided by financing activities in the first three months of 2009 consisted of net proceeds from our Line of Credit offset by payments on outstanding debt. Net cash used in financing activities in the first three months of 2008 consisted of payments on outstanding debt.

At March 31, 2009, the Company had cash and cash equivalents of $592,000.

13

Outlook

The Company's primary short-term capital and working capital needs relate to continued support of its research and development programs, exploring new distribution opportunities, focusing sales efforts on segments of the drugs of abuse testing market that will yield high volume sales, refining its manufacturing and production capabilities, and establishing adequate inventory levels to support expected sales. While the Company believes that its current infrastructure is sufficient to support its business, if at some point in the future, the Company experiences renewed growth in sales, it may be required to increase its current infrastructure to support sales. It is also possible that additional investments in research and development, selling and marketing and general and administrative may be necessary in the future to: develop new products in the future, enhance current products to meet the changing needs of the point of collection testing market, grow contract manufacturing operations, promote the Company’s products in its markets and institute changes that may be necessary to comply with various new public company reporting requirements including but not limited to requirements related to internal controls over financial reporting. However, the Company has taken measures to control the rate of increase of these costs to be consistent with any sales growth rate of the Company.

The Company believes that it will need to raise additional capital in fiscal 2009 to be able to continue operations. If events and circumstances occur such that the Company does not meet its current operating plans, or it is unable to raise sufficient additional equity or debt financing, or credit facilities are insufficient or not available, the Company may be required to further reduce expenses or take other steps which could have a material adverse effect on its future performance.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable

Item 4. Controls and Procedures

(a)Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), together with other members of management, have reviewed and evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 Rule 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based on this review and evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported in a timely manner.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal control over financial reporting during the last quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See “Note C – Litigation” in the Notes to interim Financial Statements included in this report for a description of pending legal proceedings in which the Company is a party.

Item 1A. Risk Factors

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5.  Other Information

None.

14

Item 6.  Exhibits

31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

32.1 Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

15

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN BIO MEDICA CORPORATION

(Registrant)

By: /s/Stefan Parker

Stefan Parker

Chief Financial Officer

Executive Vice President, Finance

Principal Financial Officer and duly authorized Officer

Dated: May 14, 2009

16

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Stan Cipkowski, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Bio Medica Corporation;

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 14, 2009

/s/ Stan Cipkowski

Stan Cipkowski

Chief Executive Officer

Principal Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Stefan Parker, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Bio Medica Corporation;

2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a.  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b.  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:  May 14, 2009

/s/ Stefan Parker

Stefan Parker

Chief Financial Officer

Executive Vice President, Finance

Principal Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Quarterly Report of American Bio Medica Corporation (the "Company") on Form 10-Q for the period ending March 31, 2009 as filed with the Securities and Exchange Commission on May 14, 2009 (the "Report"), I, Stan Cipkowski, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Stan Cipkowski

Stan Cipkowski

Chief Executive Officer

Principal Executive Officer

May 14, 2009

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

         In connection with the Quarterly Report of American Bio Medica Corporation (the "Company") on Form 10-Q for the period ending March 31, 2009 as filed with the Securities and Exchange Commission on May 14, 2009 (the "Report"), I, Stefan Parker, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)  The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Stefan Parker

Stefan Parker

Chief Financial Officer

Executive Vice President, Finance

Principal Financial Officer

May 14, 2009